Cephalon granted Temporary Restraining Order in AMRIX® patent litigation
Posted: 20 May 2011 | | No comments yet
The United States District Court for the District of Delaware granted a motion filed by plaintiffs Cephalon and Eurand for a TRO enjoining Mylan Pharmaceuticals and Mylan from manufacturing, using and selling its cyclobenzaprine hydrochloride extended-release capsules…
Today, the United States District Court for the District of Delaware granted a motion filed by plaintiffs Cephalon, Inc. (NASDAQ: CEPH), and Eurand, Inc., for a Temporary Restraining Order (TRO) enjoining Mylan Pharmaceuticals Inc., and Mylan Inc., from manufacturing, using, offering to sell or selling its cyclobenzaprine hydrochloride extended-release capsules, a generic version of Cephalon’s branded product AMRIX®. The TRO remains in effect pending appeal.
“We are very pleased with the Court’s decision to grant our request for a TRO,” said Jerry Pappert, Executive Vice President and General Counsel for Cephalon. “We remain confident in the strength of the patents protecting AMRIX®, and believe we have a strong case on appeal.”
